180 related articles for article (PubMed ID: 36971805)
21. Combined Quantification of
Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA
Acad Radiol; 2022 Sep; 29(9):1308-1316. PubMed ID: 34836776
[TBL] [Abstract][Full Text] [Related]
22. Comparison of [
Chen H; Pang Y; Li J; Kang F; Xu W; Meng T; Shang Q; Zhao J; Guan Y; Wu H; Xie F; Wang J; Sun L
Eur Radiol; 2023 Feb; 33(2):1329-1341. PubMed ID: 35976396
[TBL] [Abstract][Full Text] [Related]
23. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
25. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
26. The Potential Prognostic Value of Dual-Imaging PET Parameters Based on
Hou J; Long T; Yang Y; Chen D; Hu S
Mol Imaging; 2022; 2022():6511179. PubMed ID: 35368455
[TBL] [Abstract][Full Text] [Related]
27. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of [
Choi SJ; Choi SH; Lee DY; Lee JS; Kim DW; Jang JK
Eur Radiol; 2022 Jul; 32(7):4628-4637. PubMed ID: 35092473
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of [
Li C; Tian Y; Chen J; Jiang Y; Xue Z; Xing D; Wen B; He Y
Eur Radiol; 2023 Apr; 33(4):2779-2791. PubMed ID: 36394603
[TBL] [Abstract][Full Text] [Related]
30. CXCR4-Directed PET/CT with [
Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
[TBL] [Abstract][Full Text] [Related]
31. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.
Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J
Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography and computed tomography with [
Pang Y; Zhao L; Shang Q; Meng T; Zhao L; Feng L; Wang S; Guo P; Wu X; Lin Q; Wu H; Huang W; Sun L; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1322-1337. PubMed ID: 34651226
[TBL] [Abstract][Full Text] [Related]
33. Utility of 18F-AlF-NOTA-Octreotide PET/CT in the Localization of Tumor-Induced Osteomalacia.
Long T; Hou J; Yang N; Zhou M; Li Y; Li J; Tang Y; Chen D; Hu S
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4202-e4209. PubMed ID: 33864458
[TBL] [Abstract][Full Text] [Related]
34. Prospective Phase II Trial of [
Carlsen EA; Loft M; Loft A; Czyzewska D; Andreassen M; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2023 Feb; 64(2):252-259. PubMed ID: 35981899
[TBL] [Abstract][Full Text] [Related]
35. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on
Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN
Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
[TBL] [Abstract][Full Text] [Related]
36. Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using
Jha A; Patel M; Carrasquillo JA; Ling A; Millo C; Saboury B; Chen CC; Wakim P; Gonzales MK; Meuter L; Knue M; Talvacchio S; Herscovitch P; Rivero JD; Chen AP; Nilubol N; Taïeb D; Lin FI; Civelek AC; Pacak K
AJR Am J Roentgenol; 2022 Feb; 218(2):342-350. PubMed ID: 34431366
[No Abstract] [Full Text] [Related]
37. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
38. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
[TBL] [Abstract][Full Text] [Related]
39.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
40. The comparison of three different molecular imaging methods in localization and grading of insulinoma.
Chang L; Bi X; Li S; Tong Q; Gu Y; He Z; Li Y; Chen Q; Cui J; Yu H; He Q; Liu M
Front Endocrinol (Lausanne); 2023; 14():1163176. PubMed ID: 37455905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
